These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 27915497)

  • 1. Current and future development of extended-release, abuse-deterrent opioid formulations in the United States.
    Webster LR; Markman J; Cone EJ; Niebler G
    Postgrad Med; 2017 Jan; 129(1):102-110. PubMed ID: 27915497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Abuse Deterrent Formulations of Opioids in Patients With Chronic Pain in the United States: A Cost-Effectiveness Model.
    Kumar VM; Agboola F; Synnott PG; Segel C; Webb M; Ollendorf DA; Banken R; Chapman RH
    Value Health; 2019 Apr; 22(4):416-422. PubMed ID: 30975392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and impact of prescription opioid abuse deterrent formulation technologies.
    Alexander L; Mannion RO; Weingarten B; Fanelli RJ; Stiles GL
    Drug Alcohol Depend; 2014 May; 138():1-6. PubMed ID: 24613631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitigation of IV Abuse Through the Use of Abuse-Deterrent Opioid Formulations: An Overview of Current Technologies.
    Rauck RL
    Pain Pract; 2019 Apr; 19(4):443-454. PubMed ID: 30597739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abuse-deterrent opioids: an update on current approaches and considerations.
    Pergolizzi JV; Raffa RB; Taylor R; Vacalis S
    Curr Med Res Opin; 2018 Apr; 34(4):711-723. PubMed ID: 29262730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations.
    Gasior M; Bond M; Malamut R
    Postgrad Med; 2016 Jan; 128(1):85-96. PubMed ID: 26566680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain.
    Hale ME; Moe D; Bond M; Gasior M; Malamut R
    Pain Manag; 2016 Oct; 6(5):497-508. PubMed ID: 27050830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opioids with abuse-deterrent properties: A regulatory and technological overview.
    Haddox JD
    J Opioid Manag; 2017; 13(6):397-413. PubMed ID: 29308587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of prescription opioids with abuse-deterrent technology to address opioid abuse.
    Michna E; Kirson NY; Shei A; Birnbaum HG; Ben-Joseph R
    Curr Med Res Opin; 2014 Aug; 30(8):1589-98. PubMed ID: 24738694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abuse-Deterrent Opioid Formulations: A Key Ingredient in the Recipe to Prevent Opioid Disasters?
    Salwan AJ; Hagemeier NE; Harirforoosh S
    Clin Drug Investig; 2018 Jul; 38(7):573-577. PubMed ID: 29651781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
    Cicero TJ; Ellis MS
    JAMA Psychiatry; 2015 May; 72(5):424-30. PubMed ID: 25760692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges Involved in the Development and Delivery of Abuse-deterrent Formulations of Opioid Analgesics.
    Cohen JP; Mendoza M; Roland C
    Clin Ther; 2018 Feb; 40(2):334-344. PubMed ID: 29398162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Clinical Applications of Extended-Release Abuse-Deterrent Opioids.
    Vadivelu N; Schermer E; Kodumudi G; Berger JM
    CNS Drugs; 2016 Jul; 30(7):637-46. PubMed ID: 27290716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the impact of abuse-deterrent opioids (ADOs): identifying epidemiologic factors related to new entrants with low population exposure.
    Roland CL; Setnik B; Brown DA
    Postgrad Med; 2017 Jan; 129(1):12-21. PubMed ID: 27960575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of Opioid Abuse and Treatment of Opioid Addiction: Current Status and Future Possibilities.
    Park K; Otte A
    Annu Rev Biomed Eng; 2019 Jun; 21():61-84. PubMed ID: 30786212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current status and evolving role of abuse-deterrent opioids in managing patients with chronic pain.
    Webster L; St Marie B; McCarberg B; Passik SD; Panchal SJ; Voth E
    J Opioid Manag; 2011; 7(3):235-45. PubMed ID: 21823554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Impact and Application of Abuse-Deterrent Opioid Formulations in Clinical Practice.
    Lee YH; Brown DL; Chen HY
    Pain Physician; 2017 Nov; 20(7):E1003-E1023. PubMed ID: 29149148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abuse-deterrent formulations, an evolving technology against the abuse and misuse of opioid analgesics.
    Schaeffer T
    J Med Toxicol; 2012 Dec; 8(4):400-7. PubMed ID: 23073726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Projecting the cost, utilization, and patient care impact of prescribing extended release non-abuse-deterrent opioids to chronic pain patients.
    Yenikomshian MA; White AG; Carson ME; Garrison LP; Oderda GM; Biskupiak JE; Hlavacek PR; Roland CL
    J Opioid Manag; 2017; 13(5):291-301. PubMed ID: 29199395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of abuse-deterrent formulations in countering opioid misuse and abuse.
    Nguyen V; Raffa RB; Taylor R; Pergolizzi JV
    J Clin Pharm Ther; 2015 Dec; 40(6):629-34. PubMed ID: 26595258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.